Procter & Gamble Co vs Tilray Brands Inc — how do they compare? Procter & Gamble Co trades at $149.49 (market cap $344.87B), while Tilray Brands Inc trades at $4.19 (market cap $524.07M). The key difference: Procter & Gamble Co is far larger — about 658.1× Tilray Brands Inc's market cap, and Procter & Gamble Co pays a 2.94% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| PG | TLRY | |
|---|---|---|
Market Cap | $344.87B | $524.07M |
Volume | 6,423,436 | — |
Sector | Consumer Staples | Health |
52-Week High | $167.18 | $21.00 |
52-Week Low | $138.10 | $4.23 |
Enterprise Value | $370.34B | $621.22M |
Dividend Yield | 2.94% | — |
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $149.15, showing minimal daily movement with a neutral technical stance. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.59 versus $1.56 expected, and robust profitability metrics like a 50.33% gross margin. Recent developments include a multi-year WNBA partnership and ongoing dividend payments of $1.09 per share, supporting its defensive appeal amid market volatility.
PG offers stability with a 53.85% analyst buy rating and $160.50 consensus target, but premium valuations (P/E 21.65) and modest growth outlook pose near-term risks. Supply chain efficiencies and brand strength underpin resilience, though inflation and competitive pressures require monitoring for sustained shareholder returns.
TLRY trades at $4.23, down 1.63% on the day, with a bearish technical signal and negative earnings trends. The company reported a net loss of $2.19 billion in 2025 despite revenue growth to $821.31 million, reflecting deep profitability challenges. Analysts show cautious sentiment with 65% hold ratings, while recent news highlights expansion in medical cannabis and beverage segments amid ongoing regulatory uncertainty.
The outlook remains challenged by persistent losses and high debt-to-asset ratio of 12.25, though low P/S and P/B ratios suggest undervaluation. Key risks include profitability execution and federal cannabis policy shifts, while potential catalysts lie in international expansion and cost management improvements.
Trailing returns across standard periods
Latest headlines on both assets
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →